{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:56:54Z","timestamp":1790542614816,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejca.2026.117054","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:15:39Z","timestamp":1789226139000},"page":"117054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prophylactic use of G-CSFs to reduce neutropenia rates in patients treated with antibody\u2013drug conjugates: A literature review"],"prefix":"10.1016","volume":"248","author":[{"given":"Florian","family":"Scott\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Lustberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Ben Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sne\u017eana","family":"Bo\u0161njak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3728-273X","authenticated-orcid":false,"given":"Christina H.","family":"Ruhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Klastersky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4724-7871","authenticated-orcid":false,"given":"Didier","family":"Mayeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6114-1956","authenticated-orcid":false,"given":"Tim","family":"Cooksley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.117054_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104241","article-title":"Antibody-drug conjugates: prospects for the next generation","volume":"29","author":"Grairi","year":"2024","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ejca.2026.117054_bib2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2026.117054_bib3","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.117054_bib4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/jcdd10120489","article-title":"HER2-targeted therapy\u2013from pathophysiology to clinical manifestation: a narrative review","volume":"10","author":"Slavcheva","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.ejca.2026.117054_bib5","first-page":"124","article-title":"Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors","volume":"8","author":"Cheng","year":"2025","journal-title":"Antib Ther"},{"key":"10.1016\/j.ejca.2026.117054_bib6","article-title":"A paradigm shift in neutrophil adverse event grading: why now?","volume":"9","author":"Merz","year":"2025","journal-title":"Hemasphere"},{"key":"10.1016\/j.ejca.2026.117054_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102427","article-title":"Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: a review","volume":"109","author":"Blayney","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2026.117054_bib8","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00280-016-2970-5","article-title":"Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy","volume":"77","author":"Li","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2026.117054_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/annonc\/mdl337","article-title":"Diarrhea in neutropenic patients: a prospective cohort study with emphasis on neutropenic enterocolitis","volume":"18","author":"Aksoy","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117054_bib10","first-page":"4377","article-title":"Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies","volume":"24","author":"Li","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2026.117054_bib11","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117054_bib12","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.117054_othref0005","unstructured":"European Medicines Agency. Medicines, https:\/\/www.ema.europa.eu\/en\/medicines; 2025 [accessed February 2026]."},{"key":"10.1016\/j.ejca.2026.117054_bib16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.117054_bib17","unstructured":"National Comprehensive Cancer Network.NCCN Guidelines - Hematopoietic Growth Factors Version 3.2026, https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1493; 2026 [accessed February 2026]."},{"key":"10.1016\/j.ejca.2026.117054_bib18","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO-25-02938","article-title":"WBC growth factors: ASCO guideline update","volume":"44","author":"Gyawali","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117054_bib19","unstructured":"Association Francophone des Soins Oncologiques de Support. Neutrop\u00e9nie F\u00e9brile Prophylaxie, https:\/\/www.afsos.org\/wp-content\/uploads\/2014\/07\/Neutropenie-et-cancer_AFSOS.pdf; 2021 [accessed February 2026]."},{"key":"10.1016\/j.ejca.2026.117054_bib20","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1007\/s12325-018-0798-6","article-title":"Systematic review and meta-analysis of short- versus long-acting granulocyte colony-stimulating factors for reduction of chemotherapy-induced febrile neutropenia","volume":"35","author":"Cornes","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.ejca.2026.117054_bib21","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028218","article-title":"Long-acting versus short-acting granulocyte colony-stimulating factors among cancer patients after chemotherapy in China: a systematic review and meta-analysis of randomized controlled trials","volume":"100","author":"Wang","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ejca.2026.117054_bib22","doi-asserted-by":"crossref","first-page":"e1139","DOI":"10.1200\/OP.20.00994","article-title":"Economic analysis on adoption of biosimilar granulocyte colony-stimulating factors in patients with nonmyeloid cancer at risk of febrile neutropenia within the Oncology Care Model framework","volume":"17","author":"Wang","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.ejca.2026.117054_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/MS9.0000000000004732","article-title":"G-CSF biosimilars vs. originator filgrastim for febrile neutropenia prophylaxis: systematic review of cost-effectiveness, safety, and clinical outcomes","author":"Karim","year":"2026","journal-title":"Ann Med Surg"},{"key":"10.1016\/j.ejca.2026.117054_bib24","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117054_bib25","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117054_bib26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","article-title":"Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ejca.2026.117054_bib27","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa2508959","article-title":"Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117054_bib28","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117054_bib29","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117054_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1435485","article-title":"Efficacy and safety of RC48-ADC in HER2-positive and HER2-low metastatic breast cancer: a multicenter, real-world study","volume":"14","author":"Qu","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2026.117054_bib31","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.117054_bib32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/oncolo\/oyad308","article-title":"Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: the DE-REAL study","volume":"29","author":"Botticelli","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2026.117054_bib33","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.117054_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117054_bib35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117054_bib36","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged \u226560 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study","volume":"107","author":"Evens","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2026.117054_bib37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hon.2838","article-title":"Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 study","volume":"39","author":"Hutchings","year":"2021","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ejca.2026.117054_bib38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.117054_bib39","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2012.42.7211","article-title":"Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab","volume":"31","author":"Fayad","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117054_bib40","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","article-title":"Management of important adverse events associated with inotuzumab ozogamicin: expert panel review","volume":"53","author":"Kebriaei","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2026.117054_bib41","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejca.2026.117054_bib42","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.117054_bib43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.117054_bib44","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkad069","article-title":"Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis","volume":"7","author":"Suzuki","year":"2023","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.ejca.2026.117054_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103758","article-title":"Is antibody-drug conjugate a rising star for clinical treatment of solid tumors? A systematic review and meta-analysis","volume":"177","author":"Zhang","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2026.117054_bib46","doi-asserted-by":"crossref","DOI":"10.1111\/eci.70001","article-title":"Adverse events and impact on quality of life of antibody-drug conjugates in the treatment of metastatic breast cancer: a systematic review and meta-analysis","volume":"55","author":"Perachino","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ejca.2026.117054_bib47","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117054_bib48","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.117054_bib49","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12185-020-03039-w","article-title":"Safety profile of brentuximab vedotin in Japanese patients with relapsed\/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study","volume":"113","author":"Izutsu","year":"2021","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ejca.2026.117054_bib50","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.117054_bib51","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.21.00108","article-title":"Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk hodgkin lymphoma","volume":"39","author":"Kumar","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117054_bib52","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1158\/1078-0432.CCR-18-2435","article-title":"Brentuximab vedotin plus chemotherapy in North American subjects with newly diagnosed stage III or IV Hodgkin lymphoma","volume":"25","author":"Ramchandren","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.117054_bib53","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3026(23)00089-3","article-title":"Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial","volume":"10","author":"D\u00f6hner","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejca.2026.117054_bib54","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/blood-2012-03-416701","article-title":"Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004","volume":"120","author":"Hasle","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.117054_bib55","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO-24-02242","article-title":"Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma","volume":"43","author":"Bartlett","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117054_bib56","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.117054_bib57","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41416-024-02685-9","article-title":"Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom","volume":"130","author":"Hanna","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2026.117054_bib58","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1038\/s41591-024-03269-z","article-title":"Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132-002 trial","volume":"30","author":"Xu","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.117054_bib59","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117054_bib60","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117054_bib61","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000034486","article-title":"An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer","volume":"102","author":"Cheng","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ejca.2026.117054_bib62","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/10600280231164110","article-title":"Sacituzumab govitecan as a second-line treatment in relapsed\/refractory metastatic triple-negative breast cancer patients: a systematic review and meta-analysis","volume":"58","author":"Kathpalia","year":"2024","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ejca.2026.117054_bib63","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s44276-024-00106-1","article-title":"Efficacy and safety of sacituzumab govitecan Trop-2-targeted antibody-drug conjugate in solid tumors and UGT1A1*28 polymorphism: a systematic review and meta-analysis","volume":"2","author":"Sultana","year":"2024","journal-title":"BJC Rep"},{"key":"10.1016\/j.ejca.2026.117054_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103853","article-title":"Safety profile of sacituzumab govitecan in patients with breast cancer: a systematic review and meta-analysis","volume":"79","author":"Dacoregio","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2026.117054_bib65","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1200\/OP.24.00242","article-title":"Real-world clinical outcomes with sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"21","author":"Alaklabi","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.ejca.2026.117054_bib66","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab govitecan in untreated, advanced triple-negative breast cancer","volume":"393","author":"Cort\u00e9s","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117054_bib67","unstructured":"Urology Times. Sacituzumab govitecan withdrawn from bladder cancer market following negative trial, https:\/\/www.urologytimes.com\/view\/sacituzumab-govitecan-withdrawn-from-bladder-cancer-market-following-negative-trial; 2024 [accessed February 2026]."},{"key":"10.1016\/j.ejca.2026.117054_bib68","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study","author":"Pistilli","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117054_bib70","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1078155210374129","article-title":"Review of granulocyte colony-stimulating factors in the treatment of established febrile neutropenia","volume":"17","author":"P\u00e9rez Velasco","year":"2011","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"10.1016\/j.ejca.2026.117054_bib71","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf088","article-title":"Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan","volume":"30","author":"Valsecchi","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2026.117054_bib72","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1200\/JOP.18.00750","article-title":"Febrile neutropenia: an ounce of prevention or a pound of cure","volume":"15","author":"Lyman","year":"2019","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.ejca.2026.117054_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70096","article-title":"UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan","volume":"13","author":"Wong","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2026.117054_bib74","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1200\/JCO.2023.41.16_suppl.4514","article-title":"Safety analysis by UGT1A1 status of TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI)","volume":"41","author":"Loriot","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117054_bib75","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s12888-021-03514-6","article-title":"Benign ethnic neutropenia: an analysis of prevalence, timing and identification accuracy in two large inner-city NHS hospitals","volume":"21","author":"Oloyede","year":"2021","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.ejca.2026.117054_bib76","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000872","article-title":"The European guidelines on diagnosis and management of neutropenia in adults and children: a consensus between the European Hematology Association and the EuNet-INNOCHRON COST action","volume":"7","author":"Fioredda","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.ejca.2026.117054_bib77","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1111\/cas.16234","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer","volume":"115","author":"Iwata","year":"2024","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2026.117054_bib78","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s12282-024-01600-7","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable\/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study","volume":"31","author":"Yamashita","year":"2024","journal-title":"Breast Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600835X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600835X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:10:49Z","timestamp":1790539849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492600835X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":75,"alternative-id":["S095980492600835X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117054","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylactic use of G-CSFs to reduce neutropenia rates in patients treated with antibody\u2013drug conjugates: A literature review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117054"}}